Rebirth 08: Rise from copycat phones

Chapter 380 Xiluokeda is listed
The biggest news in the pharmaceutical industry over the past year was undoubtedly Galaxy Pharmaceuticals' Xylokeda.

This broad-spectrum anti-cancer drug, with its wide range of indications, incredibly good efficacy, and very low side effects, quickly attracted reports from news media around the world as soon as the first phase of clinical trials began.

At the same time, it has also attracted widespread attention from people all over the world!

There was even a scramble for Xiluokeda in some overseas regions. Later, due to the special nature of the drug, especially its urgency for critically ill cancer patients, it obtained emergency marketing authorization in many countries around the world.

The drug is approved for use in some patients with advanced cancer who are at risk of death.

This not only allowed the drug Xiluokeda to save countless lives, but also allowed the drug to begin commercial operations during the clinical trial stage, allowing Galaxy Pharmaceuticals to earn a large amount of revenue.

Although Galaxy Pharmaceuticals is not a listed company, it has not released its financial reports and sales data to the public.

However, there are still third-party data statistics agencies that have provided the global sales data of the drug last year.

According to data from several third-party statistical agencies, Xiluo Keda's global sales in 16 years reached billion US dollars, surpassing Adalimumab's sales of more than billion US dollars, becoming the world's best-selling drug.

This data also exceeded the predictions of many analytical agencies at the time. Initially, they predicted that the sales volume of Xiluokeda would be only 15 billion US dollars, but in the second half of the year, a large number of countries approved the emergency marketing authorization of the drug, even including many countries where Galaxy Pharmaceuticals had not conducted clinical trials. They also directly approved the emergency marketing authorization of the drug in their countries based on the clinical trial results conducted by Galaxy Pharmaceuticals in the United States, the European Union, China, Japan and other countries or regions.

Because this is a true life-saving drug, there are a large number of terminally ill cancer patients around the world who are waiting for this drug to save their lives... There have been many protests and even attacks for this reason, so no one is willing to bear the anger of those cancer patients and their families in this matter.

Since the big countries above have already issued emergency marketing authorization, they might as well follow suit.

This enabled Xiluokeda to quickly enter a large number of countries around the world in the second half of last year.

In this case, even though the indications of Xiluokeda last year were strictly limited to the sixteen indications that have been verified by clinical trials, and even though it was only allowed to be used by critically ill patients with a survival period of less than sixteen months.

However, the sales of this drug are still very exaggerated, directly reaching 18 billion US dollars.

Of course, this is also closely related to the high price of Xiluokeda. The medical insurance price of this drug in China is 100,000 yuan per course of treatment, while the medical insurance price in Europe and the United States is generally between 25,000 and 30,000 US dollars per course of treatment.

The above is the negotiated price of medical insurance, which can also be regarded as the wholesale price. The price is relatively cheap. If it is the retail price, the price of the drug will increase by 50% to 300% in different regions.

In some countries, the price of this drug outside of medical insurance can even reach more than 100,000 US dollars.

At the same time, the above price is only the price for a one-month course of treatment... In fact, it is the price of a box of medicine, because generally speaking, you only need to take one pill orally a day, and a box of medicine contains thirty pills, which is exactly enough for one month.

Unless the cancer is in the early stages and the symptoms are relatively mild, one course of treatment can cure it. Patients in the middle stages may need to take medication continuously for three to six months. If the case is special, such as when the cancer cells have spread on a large scale, the corresponding medication time will be longer.

At the same time, surgery may be necessary in some cases.

The Xiluokeda sold last year was mainly for critically ill patients, who often need to take the medicine for half a year or even longer.

This means that even with emergency marketing authorization, the sales of Xiluokeda will be very considerable.

This is why sales are still so huge despite so many restrictions on this drug.

It only took half a year for him to become the world's king of medicine!

Now, Xiluokeda has completed the third phase of clinical trials in some countries and has begun to formally apply for marketing authorization.

It can be predicted that the sales of this drug will see a very crazy growth rate. The $30 billion or even $40 billion predicted by many analysis agencies before may not be able to be achieved, and it may even reach $50 billion or even more.

Because over the past six months, Xiluokeda has proven its efficacy with a large number of actual treatment cases.

At present, countless common cancer patients are eagerly waiting for the official launch of the drug and then taking it.

Instead of waiting until one is about to die before being approved to use the drug.

In many cases, Galaxy Pharmaceuticals applied for a formal marketing authorization for its core product Xiluokeda, which attracted countless people's attention.

Not only domestic attention, but also foreign attention!
After all, cancer knows no borders. There are also many cancer patients in other countries, and they are also eager to wait for this drug to save their lives.

Many news media also grasped the traffic code and began to report extensively.

"What do you think of Xiluokeda's application for marketing authorization in many countries around the world? What impact will it have?"

"Xylokada, the world's leading anti-cancer drug, has officially applied for listing. Cancer patients will have a new life!"

"More than 10,000 cancer patients and their families in the United States have petitioned the FDA to approve the official launch of Xeloda as soon as possible."

The media reported on this extensively, which once again sparked a heated discussion about immunotherapy in the industry and among ordinary people.

Because Xiluokeda is a broad-spectrum anti-cancer macromolecular drug based on human immunity...The emergence of this drug, coupled with the fact that some pharmaceutical companies have previously developed an immune drug for individuals using in vitro synthesis.

This has also made immune drugs the hottest word in the medical field in recent times.

People are wondering, since this immune drug can be used to treat cancer, can it be used for other diseases?
You know, in addition to cancer, people face many other disease threats.

In this regard, many pharmaceutical giants have said that this is possible and the possibility is very high.

Galaxy Pharmaceuticals, which is at the center of the discussion, has also announced that they are developing other immune drugs and trying to develop more drugs to save people's lives.

But the problem is that the research and development of immune drugs is actually very difficult. Not to mention other pharmaceutical companies, even Galaxy Pharmaceuticals itself is still groping in the dark.

The development process of the drug Xiluokeda is full of coincidences and even uniqueness...there is almost no way to replicate its successful experience.

Even though Galaxy Pharmaceuticals has complete R&D data on the drug, it is still difficult to use this data to develop a second immune drug.

why?
Because Galaxy Pharmaceuticals still doesn't understand why Xiluokeda can treat cancer...

Although they made the medicine, they didn't know the principle behind it.

This has to be said to be extremely ironic.

Therefore, the main research work of Galaxy Pharmaceuticals in the near future is actually to study Xiluokeda itself, trying to thoroughly understand its principles.

Only by understanding the principles can we establish basic theories and then develop immune drugs in other fields based on the theories.

At the same time, Galaxy Pharmaceuticals is also conducting ongoing clinical trials on Xiluokeda, but these are not clinical trials in the conventional sense, but clinical trials for more indications.

Previous clinical trials were limited to the sixteen previously verified types of cancer, but there are many types of cancer, hundreds of them.

Galaxy Pharmaceuticals is also currently conducting clinical trials for more cancer indications so that Xiluokeda can also be used against these cancers.

----

While there were many comments from the outside world, China took the lead in completing the submission of various data from the first three phases of clinical trials by Galaxy Pharmaceuticals, and then officially approved the listing of Xiluokeda.

As soon as the news came out, many cancer patients and their families in the country rushed to celebrate.

This means that ordinary cancer patients in the country can get a prescription for the drug, take it, and cure their cancer as long as it is within the indications.

After China granted Xiluokeda the marketing authorization, the pressure was soon put on many overseas countries.

However, this time, drug regulatory agencies in many overseas countries have learned their lesson and quickly approved Xiluokeda's marketing authorization.

In mid-February, Galaxy Pharmaceuticals' Xiluokeda had been approved in more than a dozen countries around the world where clinical trials were being conducted.

Many countries that have not conducted clinical trials have also cited the clinical trial data and approval results of the above-mentioned countries, and then successively granted Xiluokeda marketing authorization.

If nothing unexpected happens, Xiluokeda, this ace drug, will be launched in hundreds of countries around the world... Of course, in many countries, this drug is only imported and sold in regular retail, and is not included in the local country's medical insurance. The main reason is that Galaxy Pharmaceuticals and local medical insurance have not reached a consensus.

Galaxy Pharmaceuticals has maintained an attitude of striving as much as possible to allow the drug to enter the local country's medical insurance market...but if the other party's conditions are too harsh, then it will give up entering the local medical insurance market and sell it outside of regular medical insurance.

As Xiluocida has successively completed marketing authorization in hundreds of countries, external analysts have once again raised the sales volume of the drug.

They predict that the drug's global sales are expected to exceed US$50 billion, or even reach over US$60 billion, making it a super drug that other types of original drugs can't even dream of.

Galaxy Pharmaceuticals instantly became the world's second largest pharmaceutical company.

The revenues of traditional giant pharmaceutical companies such as Johnson & Johnson, Roche, Pfizer and Novartis have been impacted by Galaxy Pharmaceuticals since last year, and if nothing unexpected happens this year, the impact will be even greater. At least they will lose a large part of the market in the field of anti-cancer drugs, which will inevitably lead to a certain degree of decline in their revenues. Pharmaceutical companies that have partially relied on anti-cancer drugs in the past will face a huge impact.

Some analysts even believe that as the market for this broad-spectrum anti-cancer drug Xilokeda continues to expand this year, more doctors and patients will become aware of and use the drug, and Xilokeda's sales are expected to increase further.

It may even reach over 100 billion US dollars in the future.

This is a truly super medicine! After the statistics and forecasts of these external analysis agencies were released, they attracted a lot of attention...

Many people want to conduct in-depth analysis and dig out more information about the company Galaxy Pharmaceuticals.

Because according to the information released by Galaxy Pharmaceuticals, Galaxy Pharmaceuticals is a multinational pharmaceutical company headquartered in Shanghai, China, with R&D centers or production bases in more than a dozen countries around the world.

It has wholly-owned subsidiaries in the United States, Europe, India, South Africa, Japan and other places, and owns many local drug brands. However, its previous business involved some insignificant generic drugs and medical equipment businesses that did not contain high-tech content.

But people are still very confused... How did such a company suddenly rise? I have never heard of it before.

People don’t know that Galaxy Pharmaceuticals did not rise suddenly!
Galaxy Pharmaceuticals is just the commercialized part of Galaxy Life, and the history of Galaxy Life can be extended to 09.

It’s just that the research field of Galaxy Life is too sensitive. It is an enterprise invested and established by a group of super-rich people in pursuit of eternal youth and longevity. If it is announced, the impact will not be very good.

A large amount of information about Galaxy Life is hidden, which means that Galaxy Pharmaceuticals, which relies on Galaxy Life, is like a monkey jumping out of a stone, which is very confusing.

It's just that, it's not important.

The relationship between Galaxy Pharmaceuticals and Galaxy Life is known to everyone who should know, and it is useless to ask about it if you don’t want to know.

Moreover, not many ordinary people really pay attention to the details of Galaxy Pharmaceuticals. They are more concerned about Xiluokeda, the super medicine king!

Xu Shenxue also paid personal attention to the global listing of Xiluokeda, but did not intervene too much.

Anyway, the medicine has been made, and we just need to go into the market and sell it step by step.

Then, after having substantial revenue, we will establish a global R&D and sales system and enter into more pharmaceutical or medical device businesses.

At the same time, a large amount of funds will be provided to Galaxy Life to support Galaxy Life's research and development in the field of life and health.

Galaxy Life has many research projects in the field of life, and they are very expensive. In the past, it could only rely on funding from many super-rich people.

Now we can rely on Galaxy Pharmaceuticals to become self-reliant.

this point is very important.

Xu Shenxue personally convened a high-level meeting regarding the subsequent development of Galaxy Life and Galaxy Pharmaceuticals, at which the future development direction of Galaxy Life and Galaxy Pharmaceuticals was finalized.

Needless to say, as for galactic life, we will continue to work hard in the field of life, try to achieve technological breakthroughs, extend human lifespan, or at least ensure that people can maintain better body functions when they get old.

The realm of life is the original goal of galactic life and the only goal at present.

As for Galaxy Pharmaceuticals, it continues to develop various new drugs, especially immune drugs, which has opened a window for research and development. This field is very important.

At the same time, we must also carry out research and development of various conventional drugs, such as some vaccines or other drugs, and even carry out research and development of some generic drugs.

There is also the field of medical devices, such as various implants, such as heart stents, dentures and many other medical consumables.

Finally, it cooperates with Zhiyun Group and other companies under Xu Shenxue to develop some cutting-edge medical equipment, such as surgical robots.

Basically, we will try everything we can to improve the company's business types, instead of having only one product, Xiluokeda, and some generic drugs with little revenue as it is now.

We will even conduct some appropriate research in the field of life in space, such as human hibernation technology, to solve the deterioration of human body functions in the space environment and other problems.

A multinational pharmaceutical giant should act like a multinational giant!

We don't want to have everything, but we should at least be involved in most areas, and then carry out some cutting-edge research and development in the life and medical fields.

Based on this strategic meeting, the basic development strategies for Galaxy Life and Galaxy Pharmaceuticals for the next few years have been finalized.

Xu Shenxue was also able to shift his attention from the medical field to the traditional smart terminal field!

In mid-March, Zhiyun Group will hold a spring press conference, and plans to release a series of A series mobile phones, C series mobile phones and SX series mobile phones at the spring press conference. At the same time, it will also release a new generation of tablets and smart watches, two major smart terminal ecosystem products.

Each of these smart terminal products is a very important product, and when added together they can generate tens of billions of dollars in revenue.

At the same time, the period from March to June is also the peak period for many mobile phone manufacturers to release new mobile phones to seize the market.

The main reason is that Zhiyun Group released the S series of mobile phones in September, and Apple released its flagship phone in October. The flagship phones of these two companies are too strong, and the fierce competition between them on a global scale will lead to a very cruel clearance situation.

Most mobile phone manufacturers will choose to avoid releasing their flagship phones during these months.

The best time period is the first half of the year... Although other models of Fruit and Zhiyun were released in the first half of the year, their influence was not that great, which left room for other mobile phone manufacturers to survive.

Considering that it will take some time for hot marketing and sales after the release of a mobile phone, it is necessary to sell as many mobile phones as possible before the release of the S series mobile phones to avoid the company's mobile phones being lost in the sea after the release of the S series mobile phones.

Therefore, most of these mobile phone manufacturers tend to choose to release their new generation of flagship phones in March.

This is the case for Four Star and Weiku Electronics.

Basically, the six months from March to September is a difficult stage for these mobile phone manufacturers. Whether they can sell more high-end flagship phones depends on how they sell in the past six months.

As for the rest of the time...the pressure from the Zhiyun S series and Apple's flagship phones is too great and will directly overwhelm them.

However, in the past few years, Zhiyun Group realized the market gap in the first half of the year and gradually put some models in the spring launch conference, first the SX series, then the C series, and then the A series.

On the one hand, it allows these models to avoid the strong impact of their own S series models.

On the other hand, the purpose is to fill the market gap in the first half of the year and use these models to compete with models from other manufacturers.

While Zhiyun Group was preparing for its spring press conference, Xu Shenxue received some bad news from Yihai Technology.

Doudong Video, a subsidiary of Yihai Technology, has encountered strong resistance in some countries and faces the risk of being banned.

And the reasons vary in different regions...

In some countries, the reason is that it has an adverse impact on young people, while in some places it is said to be a threat to national security, in some places it is said that personal privacy data is not safe, and there are some other messy reasons.

“This is not the first time that Diaodong Video’s overseas operations have been threatened. In fact, since our product was launched globally, it has become a very popular social platform in the local area in a very short period of time, and then it has continued to face various threats!”

"Last year, some countries banned their official institutions from installing our jumping videos, and some countries with limited communication directly blocked them!"

"But this year, the situation has become even more serious!"

Huang Jianian, CEO of Yihai Technology, reported to Xu Shenxue: "In response to the problem of limited access to short videos, we have gradually adjusted our business strategy for the short video track last year and started to launch localized short video platforms in local countries through investment and cooperation. Currently, we have launched localized short video platforms in Indonesia, India and other places."

"However, these localized short video platforms are limited by the small size of the local market, so it is difficult to operate them!"

“Therefore, the focus of our short video business is still on Doudong Video, and this part of the business is now facing a relatively large threat!”

"Of course, even so, we still have absolute control over the entire short video track. The top ten short video social platforms in the world are all products of our company or joint ventures."

"The problem we are facing now is that there are too many products, and it is difficult to connect the data and form a global ecological chain. This will pose a big challenge to our subsequent short video business layout!"

After Xu Shenxue carefully read the recent report of Jump Video, he said: "Many problems of Jump Video are unavoidable, because it is a global product. We cannot change it for the situation of a certain country, so Jump Video will continue to implement the existing strategy. If it can enter, it will enter. If it can't enter, forget it. If they are willing to isolate themselves from the world, we don't need to worry about them!"

"But please note that we need to further strengthen the content supervision of Doudong Video. I don't want to see any inappropriate content on it. In the field of content supervision, you can contact the Artificial Intelligence Research Institute. Their AI technology can help you solve these problems!"

It is worth mentioning that although there are domestic and international versions in Jump Video, in fact, the only difference is in the interface, and the content is actually unified globally... It’s just that in order to avoid trouble, Jump Video has diverted domestic and foreign IPs.

Coupled with the limitations of big data, in fact most of the videos people see are domestic videos.

At the same time, the content supervision in Jump Video is actually very strict... at least it is very strict in terms of relevant laws and regulations in China. After all, this is an APP that is aimed at global users. Yihai Technology does not want something that is easy to cause trouble to appear on it, so the content supervision is very strict, especially for overseas IPs.

After all, when it comes to content management, Jump Video enforces Chinese laws!
This is also the reason why many countries have opinions about Jump Video. This Jump Video is actually operated by a Chinese company. The sensitive data is also in China, and it is an APP that complies with Chinese laws... but it is also aimed at overseas users.

This also means that there will be some content that is not a problem in China but is very unfriendly to some overseas countries.

Basically, as long as the content has nothing to do with China, Jump Video will leave it alone... The main principle is that you foreigners can criticize each other and say whatever you want.

But if you dare to say that some illegal content in China is detected by big data, we will provide a one-stop service of deletion and account blocking.

"In countries where Dianping Video cannot enter and where the population is relatively large, we will continue to implement the localized short video strategy and launch apps for the local market. We will do both internationalization and localization... No matter what, we have a huge leading advantage in the short video field by relying on our big data algorithm advantages, so we must firmly grasp the entire short video track."

(End of this chapter)